Novartis Says 'No' on Alnylam IP Option as Alternate RNAi Approaches Gain Traction | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals last week disclosed that long-time partner Novartis has decided not to acquire broad, non-exclusive access to the RNAi drug shop's intellectual property and technologies — a transaction that would have been worth $100 million to Alnylam.

Concurrent with the announcement, Alnylam said that it was cutting between 25 percent and 30 percent of its workforce, which is expected to cost up to $3 million in one-time charges this year but save the company $25 million in 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.